Picard Medical: A Tale of Surgical Innovation and Shareholder Litigation

Picard Medical advances its FDA-approved artificial heart while facing class action lawsuits over a 60% stock drop and a shareholder vote to double its share count.

The story of Picard Medical presents a stark contrast between clinical advancement and capital market turmoil. As the company achieves significant milestones with its artificial heart technology, it simultaneously faces a barrage of legal challenges from shareholders alleging securities fraud.

Shareholder Lawsuits Loom Over Promotional Claims

Significant legal pressure is mounting against the company. Multiple U.S. law firms have filed class action lawsuits covering the period between September and October 2025. The core allegation is that investors were misled by a coordinated promotional campaign on social media platforms.

Concurrently, insiders are accused of conducting extensive stock sales through offshore accounts while the share price was allegedly artificially inflated. The impact on shareholders was severe: on October 24, 2025, the stock price collapsed by 59.8%, plummeting from $13.20 to $5.31. Deadlines for affected investors to join these legal actions are set for April 3 and April 13, 2026.

A Clinical Beacon: The SynCardia Total Artificial Heart

Amidst this legal strife, the company's medical progress continues. Picard Medical recently conducted a specialized training session for leading heart surgeons at Houston Methodist Hospital in Texas. The focus was the "SynCardia Total Artificial Heart" (STAH), which holds the distinction of being the only artificial heart with approvals from both the U.S. FDA and Health Canada.

The system's clinical foundation is robust, with more than 2,100 implants performed globally across 27 countries. Further enhancing the technology, Picard Medical launched new FDA-approved connector protective covers in January of this year, designed to improve patient comfort and system reliability.

Share Authorization Vote Could Double Available Stock

A pivotal decision regarding the company's capital structure is scheduled for March 10, 2026. During a virtual annual general meeting, shareholders will vote on a proposal to double the number of authorized common shares from 150 million to 300 million.

This substantial expansion is partly linked to securing a $15 million credit facility established the previous year. With approximately 73.7 million voting shares currently outstanding, approval of this measure would significantly increase the potential for future equity dilution.